Winrevair (sotatercept-csrk), an injection therapy approved for adults with pulmonary arterial hypertension (PAH), is now covered by several of Canada’s publicly funded health programs. The therapy’s developer Merck, known as MSD outside the U.S. and Canada, announced that Winrevair has been added to the public drug formularies…
Discussion
A decade later, I still remember standing in the kitchen on a phone call that would change my life. On that morning in March 2016, I left my apartment and returned nearly two weeks later with a pulmonary hypertension (PH) diagnosis. I never thought I’d reach this milestone: living…
Measuring levels of tiny pieces of genetic material in the blood, known as microRNAs, may help identify group 2 pulmonary hypertension (PH), according to a new study. “We identified a set of circulating [microRNAs] that are differentially expressed in Group 2 PH and correlated with disease severity,” researchers wrote…
A study found that a naturally occurring signaling molecule called C-type natriuretic peptide (CNP) reduced the severity of pulmonary arterial hypertension (PAH) in mice. “This study highlights the important role of [CNP] signaling in the [disease development] of PAH and suggests that modulation of this pathway may provide a…
Discussion
Discussion
Discussion
Discussion
Discussion
Discussion
Get regular updates to your inbox.
